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 “STUDY ON CLINICAL PROFILE OF CEREBRAL 
VENOUS THROMBOSIS” 
BACKGROUND: 
Cerebral venous thrombosis (CVT) refers to the thrombosis of dural venous 
sinuses or the cerebral veins. Once considered a rare disease, CVT is now being 
recognized with increasing frequency especially in South Asian countries including 
India. It is an important cause of young strokes in India especially among woman. 
Though the prognosis is good in majority of patients, it is a potentially life 
threatening disease requiring early clinical suspicion and prompt diagnosis. 
However the diagnosis may be challenging in certain cases due to varied clinical 
presentation and there is a substantial difference in predisposing factors, 
presentations, therapeutic options, and outcome between developed and 
developing countries. The objective of our study was to study the demographic, 
clinical, etiological, radiological and prognostic characteristics of the disease in 
patients admitted with CVT in our hospital. 
METHODS: 
This was a cross sectional study conducted on 45 patients admitted with CVT in 
Thanjavur medical college hospital, Thanjavur satisfying the inclusion and 
exclusion criteria. Detailed history, neurological examination, brain imaging with 
CT and MRI with MRV, routine and specific laboratory investigations as required 
were done in all patients and we analysed the demographic factors, clinical 
presentation, etiology, radiological features and outcome in these patients. 
Factors associated with good and poor outcome were also analysed. 
RESULTS: 
In our study, CVT was 3 times more common in females than in males especially 
those between the age group of 21 to 30 years. Majority of patients presented 
subacutely. Headache was the most common symptom and papilledema was the 
most common sign. 28% of patients presented with headache as an isolated 
symptom. Other common presentations were altered sensorium, focal motor 
deficit, generalized seizures and delirium. Puerperium was the leading cause of 
CVT in our study. Superior sagittal sinus and right transverse sinus were the most 
common sinuses involved by MRI with MRV. Most common finding in CT Brain 
was haemorrhagic infarct though CT Brain was normal in about 26 to 27 % of 
patients. In our study, the mortality rate was 11% and the morbidity rate was 
17%. Presentation with Isolated intracranial hypertension syndrome was 
associated with good outcome. Age ≥35 years, GCS score of <9 and coma at 
presentation were associated with poor prognosis.  
 
CONCLUSION: 
 
1. CVT has a wide range of clinical presentation. 
 
2. CVT should be suspected, 
 
i) Whenever a young adult presents with symptoms and signs of raised 
intracranial tension with or without other neurological symptoms. Examination of 
the fundus to rule out papilledema is an important tool in arriving at a diagnosis in 
such cases of CVT.  
 
ii) Whenever a young adult presents with stroke especially in the absence of 
vascular risk factors.  
 
iii) Whenever a peripartum female presents with neurological symptoms in our 
setting. 
 
iV) Whenever imaging of the brain shows haemorrhagic infarct especially in non 
arterial territories. 
 
3. Diagnosis should be confirmed by MRI with MRV whenever possible. 
  
4. In general, the prognosis is good in CVT; however extravigilance may be 
required in patients who present with poor prognostic factors. 
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INTRODUCTION 
Cerebral venous thrombosis (CVT) refers to the thrombosis of dural venous 
sinuses or the cerebral veins. It is a disease of young to middle-aged people and is 
more common in females
1,2,3
. It is a potentially life threatening condition requiring 
early clinical suspicion and prompt treatment.  
Though most of the patients have an excellent outcome if treated early and 
appropriately, diagnosis may get delayed by the wide clinical spectrum of 
symptoms, various forms of initial presentation, obscuring of symptoms and signs 
by the underlying disease like meningitis and normal findings in neuroimaging. 
CVT has an extremely diverse clinical features, predisposing factors, brain imaging 
findings and outcome
4.
 There may be a substantial difference in predisposing 
factors, presentations, therapeutic options and outcome between developed and 
developing countries. For example, International Study on Cerebral Vein and 
Dural Sinus Thrombosis (ISCVT) 
3
reported obstetric CVT in only 20% of cases as 
compared to reports from Mexico and India, which report a much higher 
frequency 
5,6
. In addition there is variability among different developing 
countries
5
. 
2 
 
The incidence of CVT is uncertain since it has a wide range of clinical 
manifestations 
7
. Once considered a rare disease based on autopsy studies, CVT is 
now recognized with increasing frequency due to enhanced clinical awareness 
and improved non invasive imaging modalities available now. Recently Panagariya 
et al 
8
 reported that 17% of all strokes and half of all strokes in young people are 
due to CVT. 
CVT has a specific geographic distribution, the incidence being higher in South 
Asia and the Middle east
9,10
. Most studies from India have reported a large 
number of cases; hence the incidence in India is not as rare as assumed earlier
10
. 
In India, CVT accounts for 10-20% of young strokes
10
. However no well designed 
large scale epidemiologic study on CVT has been conducted in South Asia, where 
it is comparatively frequent. 
These factors prompted us to study the clinical profile and to evaluate the 
demographic, clinical, etiological, radiological and prognostic characteristics of 
the disease among patients admitted with CVT in Thanjavur Medical College 
hospital, a major tertiary care hospital for the people in and around Thanjavur 
district. 
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AIM AND OBJECTIVE 
AIM 
To observe the demographic factors, clinical manifestations, risk factors and also 
the neuroimaging, laboratory, outcome data in 45 patients of cerebral venous 
thrombosis. 
OBJECTIVE 
To evaluate the demographic, clinical, etiological, radiological and prognostic 
characteristics of the disease in patients admitted in our hospital.  
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REVIEW OF LITERATURE 
INTRODUCTION 
Cerebral venous thrombosis (CVT) is defined as thrombosis in the dural venous 
sinuses or the cerebral veins
24
.  It is considered an uncommon cause of stroke and 
its incidence is much less common than cerebral arterial thromboembolism 
24
. But 
in India, CVT accounts for 10-20% of young strokes 
10
. 
The clinical features are diverse hence CVT is more challenging to diagnose than 
other types of stroke. Most patients have an excellent outcome if treated early 
and appropriately. But it is a potentially life threatening condition requiring early 
clinical suspicion and prompt treatment. 
EPIDEMIOLOGY: 
Most of the initial studies on CVT were autopsy studies performed in western 
countries. The largest autopsy  study reported incidence of CVT  as  9% 
25
.The 
estimated incidence of CVT, based on autopsy studies would be about one to two 
cases per million. However these autopsy studies are biased because they reflect 
severe fatal cases of CVT alone. They created an impression that CVT is a disease 
of rarity. However subsequent larger clinical studies disproved this fact.  
5 
 
Most of these studies were from European countries. In a hospital based series in 
Portugal incidence of CVT was 0.22/100000/year 
26
.In Hongkong the rate among 
admitted patients was 3.4/100000/year 
27
. In Isfahan, Iran the annual frequency 
of CVT was 1.23/100000/year 
28
. Daif et al from Saudi Arabia reported a frequency 
of 7 per 100,000 hospital patients, in 1995 
29
.No large multi-center or multi-
national data base or registry reported data from Asian countries. Studies from 
India on CVT have proved that CVT is more common in the developing countries 
of Asia than in the western world 
10
. 
CVT is not uncommon in Asia especially in the South Asian subcontinent including 
India, Pakistan and Bangladesh 
30
. Recently, Panagariya et al from India reported 
that 17% of all strokes in India are due to CVT. They also noted that half of all 
young strokes in India are due to CVT and that 38% of all women who 
experienced stroke had venous stroke 
8
. Hence CVT is no longer considered a rare 
disease. 
Review of CVT cases from Asian countries suggest differences in risk factors and 
outcome in these patients as compared to European studies 
30 
.The largest clinical 
series, the International Study on Cerebral vein and dural sinus thrombosis 
6 
 
 (ISCVT) reported that 50% of these cases were related to oral contraceptive pills 
(OCP), 6% were due to pregnancy and 14% were secondary to puerperium 
3
.A 
study of 182 adult patients with CVT from USA reported 7% were due to 
pregnancy and puerperium and 5% related to OCP use
31
. A study from Pakistan 
reported that 17% were due to pregnancy and puerperium and 5% related to OCP 
use
5
. Cantu from Mexico reported 59% cases due to pregnancy and puerperium
32
. 
Although rare, CVT is a well recognized disorder in children, with approximately 
half of the cases occurring in neonates and young infants
33
. In adults CVT affects 
patients who are younger than those with other types of strokes and the 
incidence apparently decreases in older subjects. The median age in the ISCVT 
cohort was 37 years
10 
with only 8 % of the patients older than 65 years. According 
to an Indian study, the mean age of patients with CVT was 32.27 years 
6
. 
CVT is more common in females than males. Male to Female ratio in ISCVT was 
1:2.9 
3
. Ameri and Bousser reported a female-to-male ratio of 1.29:1 in their 
study
4
 similar to the observations of Ferro et al 
34
. Most recent cases reported in 
adult women are in association with puerperium 
33
.
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VENOUS ANATOMY 
 The anatomy of the cerebral veins and sinuses is subject to considerable 
individual variation in size and patency 
35
.  
 The Cerebral venous system includes the cerebral veins and dural venous sinuses.  
Dural venous sinuses: 
There are 2 groups of dural venous sinuses, superior and inferior. 
Superior group collects major part of the blood of the brain. It includes superior 
sagittal sinus (SSS), inferior sagittal sinus, transverse sinus, straight sinus and 
sigmoid sinuse. The inferior group which drains the basal and medial parts of 
undersurface of brain, the orbits and the sphenoparietal sinus collects at the 
cavernous sinus. Cavernous sinuses connect with the lateral sinuses via superior 
and inferior petrosal sinuses and with the pterygoid plexus. 
The superior sagittal sinus courses over the superior border of falx cerebri, it is 
joined by the straight sinus to form the Tocular Herophili. From this confluence 
venous blood drains into the 2 lateral sinuses which drain into jugular bulbs and 
then into the Superior vena cava. 
8 
 
There are several anatomic variations of the dural sinuses. The most important 
are atresia of the anterior part of the superior sagittal sinus, duplication of the SSS 
mainly in its posterior part, asymmetry of the transverse sinus with dominance of 
right transverse sinus and aplasia or hypoplasia of the posteromedial segment of 
the left transverse sinus. Due to these variabilities, the angiographic diagnosis of 
cerebral vein or dural sinus thrombosis can be challenging. 
Cerebral veins: 
Cerebral veins include superficial venous system, deep venous system and 
posterior fossa veins.  
Superficial cerebral veins course over the surface of brain. They drain the major 
part of cerebral cortex .They have no valves and have several anastamosis. 
These superficial cortical veins drain into the superior sagittal and lateral sinus. 
These smaller veins show considerable variation in number and location except 3 
large ones namely the large vein of Trolard, large vein of Labbe and the vein of 
Rosenthal. 
The deep cerebral veins drain the inferior frontal lobe, most of the deep white 
matter of cerebral hemisphere, the corpus callosum, basal ganglia and upper 
9 
 
brainstem. It includes the internal cerebral vein and basal veins of Rosenthal that 
join to form the Great vein of Galen which drains into the straight sinus. These 
venous systems are more constant in size and course. 
The posterior fossa has large variations in venous drainage patterns: those in the 
anterior drain into petrosal sinuses, those in the upper third drain into the vein of 
Galen system and those in the posterior drain into the lateral sinuses. 
Superior sagittal sinus and the lateral sinuses are the most commonly affected 
sinuses in CVT, followed by the straight sinus and the cavernous sinus 
36,37
. 
Thrombosis of Galenic system or isolated involvement of cortical veins is 
infrequent. 
10 
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PATHOPHYSIOLOGY:  
Two major mechanisms 
37 
occurring in the pathophysiology of cerebral venous 
thrombosis are, 
1. Thrombosis of cerebral veins or dural sinus, leading to cerebral lesions. 
2. Thrombosis of dural sinus, resulting in disturbance of CSF absorption and 
increased intracranial pressure. 
 First, thrombosis of cerebral veins or sinuses results in increased venular and 
capillary pressure. As local venous pressure continue to raise, decreased cerebral 
perfusion results in ischemic injury and cytoxic edema, disruption of blood brain 
barrier leads to vasogenic edema and venous and capillary rupture culminates in 
parenchymal hemorrhage. 
Obstruction of cerebral sinuses may also result in decreased cerebrospinal fluid 
absorption which normally occurs through arachnoid granulation into the 
superior sagittal sinus. Thus thrombosis of cerebral sinuses not only increases 
venous pressure also impairs CSF absorption and ultimately leads to increased 
intracranial pressure. Increased intracranial pressure aggravates venular and 
capillary hypertension and leads to parenchymal haemorrhage, vasogenic and 
cytotoxic edema. 
12 
 
Experimental animal data suggests that vasogenic edema occurs earlier in venous 
stroke than in arterial stroke and cytotoxic edema is far less common in venous 
stroke 
38
. 
After venous occlusion large areas of brain may be functionally and metabolically 
disturbed, but not irreversibly. Reversibility is very typical of venous lesions, 
reflected by a favourable clinical recovery and vanishing lesions on 
neuroimaging
39
. 
Occlusion of one of the larger venous sinuses is not likely to cause localized tissue 
damage unless there is involvement of cortical veins or the Galenic venous system 
since alternate drainage routes will suffice .Thrombosis in cerebral veins, with or 
without dural sinus thrombosis causes multiple venous infarcts 
24
. 
TYPES OF CEREBRAL VENOUS THROMBOSIS:  
Intracranial venous thrombosis can be classified based on etiology 
33
 as 
1. Septic and 
2. Aseptic  
Septic CVT most often involves the cavernous sinus and is relatively infrequent 
nowadays 
33
. 
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Aseptic CVT is divided into 
1. Dural venous thrombosis 
2. Deep venous thrombosis and  
3. Cortical or Superficial vein thrombosis 
ETIOLOGY: 
A large number of conditions are known to cause or predispose to CVT. 
They include
40 
1. Prothrombotic conditions: 
Genetic 
 Protein S/C deficiency 
Antithrombin III deficiency 
Factor V Leiden mutation 
G20210A prothrombin gene mutation 
Plasminogen deficiency 
Increased coagulation factor VIII 
14 
 
Acquired  
  Antiphospholipid antibody syndrome 
 Hyperhomocystinemia 
2. Infections: 
Central nervous system (e.g.,abscess,meningitis) 
Ear, sinus, mouth, face and neck (e.g.otitis,mastoiditis,tonsillitis) 
Systemic infections (e.g.sepsis,endocarditis,tuberculosis,HIV) 
3. Inflammatory diseases: 
Systemic lupus erythematosus 
Behcet’s disease 
Sjogrens’s syndrome 
Wegner’s granulomatosis 
Temporal arteritis 
 Thromboangitis obliterans (Bueger’s disease) 
Inflammatory bowel disease 
15 
 
Sarcoidosis 
4. Malignancy: 
Central nervous system (meningoma,metastasis,medulloblastoma) 
Solid tumor outside the central nervous system 
Haematologic (leukemias,lymphomas)  
5. Hematological conditions: 
Sickle cell disease or trait 
Iron deficiency 
Paroxysmal nocturnal hemoglobinuria 
Thrombocythemia (primary or secondary) 
Polycythemia (primary or secondary) 
Disseminated intravascular coagulation
33 
6. Pregnancy and puerperium 
7. Other disorders: 
Dehydration 
16 
 
Congenital heart disease 
Nephrotic syndrome 
Diabetic ketoacidosis 
Thyroid disease (hyper or hypothyroidism) 
Dural fistula, arachnoid cyst 
8. Other precipitants: 
Head trauma 
Myelography, intrathecal steroids, lumbar puncture 
Neurosurgical procedures 
Irradiation 
Jugular catheter occlusion 
Drugs (oral contraceptives, hormone replacement therapy, androgens,   
steroids, sildenafil, l-asparaginase, cyclosporine, tamoxifen etc.) 
Atleast one risk factor can be identified in more than 85% of patients with CVT 
and multiple risk factors in about half of the patients 
3
. 
17 
 
The more frequent risk factors are prothrombotic conditions, oral contraceptive 
use, pregnancy / puerperium, infection and malignancy 
3
. 
A prothrombotic condition was identified in 34% of patients in the ISCVT cohort, 
being genetically determined in 22% patients 
3
.  Most common among them are 
Prothrombin gene mutation, Factor V leiden mutation and Anticardiolipin 
/antiphospholipid antibody syndrome 
3,41
. Less common are protein C/ protein S 
deficiency and antithrombin III deficiency 
41
.  
Infective causes of CVT are rare now and they account for only 6 to 12 % of 
cases
3,42
. In developing countries, systemic and nervous system infections may 
remain an important cause of CVT (18%) 
5
. 
About 7.4% of cases of CVT are due to cancers of which 2.2% are due to CNS 
malignancy, 3.2% are due to solid tumors outside CNS and 2.9% are due to 
hematological malignancies 
3
.  
In neonates, acute systemic illness such as perinatal complications and 
dehydration were frequent accounting for 84% of cases 
43
.  
In older children, head and neck disorders, mostly infections and chronic systemic 
disorders account for most of the cases.  
18 
 
The most common risk factor in young women is oral contraceptive use. In the 
metaanalysis done by Dentali and colleagues 
44
, risk of DVT was reported to be 6 
times higher in women taking oral contraceptives than those not taking OCP. 
Another frequent risk factor is pregnancy and puerperium
3,32,45
, more commonly  
in less developed world regions with higher pregnancy rates 
46
. 
In the ISCVT cohort, thrombophilia, malignancy and hematologic disorders such as 
polycythemia were the most common risk factors for CVT in the elderly 
47
. 
However in 37% of elderly,no risk factor could be identified. 
Despite extensive search, no underlying risk factor is found in 20% of adult 
patients with CVT 
24
. 
CLINICAL FEATURES: 
The clinical manifestations of Cerebral venous thrombosis are highly variable 
42
. In 
more than 50% of the cases, it is subacute in onset, in onethird of patients it is of 
acute onset and in a few cases it is chronic 
40
.  
Symptoms and signs of CVT are classified into 3 more frequent syndromes as 
follows, 
19 
 
1. Isolated intracranial hypertension syndrome which consists of headache with 
or without vomiting, papilledema and visual troubles 
48
. 
2. Focal syndrome which includes focal deficit, seizures or both. 
3. Encephalopathy which consists of bilateral or multifocal signs, delirium or 
consciousness disturbances 
26,42
. 
Less frequent syndromes include cavernous sinus syndrome and syndromes 
involving multiple palsies of lower cranial nerves. Multiple transient ischemic 
attacks have also been reported as a manifestation of CVT 
49
. 
In perhaps one-quarter of ‘benign intracranial hypertension’ patients the cause is 
dural sinus thrombosis
24
. In these cases, there is seldom propagation of 
thrombosis into the cerebral veins with venous infarction and focal neurological 
features. Indeed, the clinical picture seems identical to that of idiopathic benign 
intracranial hypertension. The prognosis is very good, although a few patients 
may be left blind due to optic atrophy. 
Clinical signs and symptoms depend on the following factors  
1. Gender of the patient 
43,47
.   
2. Age of the patient 
43,47
. 
20 
 
3. Interval from onset to presentation 
50,51
. 
4. Presence of parenchymal lesions. 
5. Type and number of involved sinuses and veins. 
In neonates, presentation is often nonspecific. Most common among them are 
seizures, respiratory distress, poor feeding, lethargy, hypertonia or hypotonia 
52
. 
Older children manifest like adults. They most commonly present with head ache 
with or without vomiting, papilledema, sixth cranial nerve palsy, motor deficit, 
seizures and altered consciousness
43,53
. 
In elderly patients headache is less common 
47  
, decreased vigilance and mental 
symptoms are more common than younger patients
40,47
. 
Upto 90% of patients with CVT complain of headache which is the most frequent 
symtoms and often the initial one
40
.  By ISCVT, head ache was the only symptom 
in 9% of patients with CVT
40
. Headache associated with CVT has no specific 
characteristics, it may be acute or chronic, localized or diffuse 
54
.The localization 
of headache has no relationship with the location of the occluded sinuses or the 
parenchymal lesions 
55
. CVT associated headache can be more severe and acute 
than other types of headache in some cases requiring emergency care. The most 
21 
 
frequent type of headache is the intracranial hypertension variety, a severe, 
generalized headache worsening with valsalva’s maneuvers and when the patient 
is lying down. Migraine with aura has also been reported
56 
.Sudden headache, 
often with blood in the CSF, is a very rare presentation and clearly can be 
confused with spontaneous subarachnoid haemorrhage due to aneurysmal 
rupture
57
.  CVT must also be included as a possible cause of persisting headache 
after lumbar puncture. 
Papilloedema occurs in about 50% of patients 
24
 and is more frequent in chronic 
cases. Seizures, focal deficit, alterations in conscious level occur in about 30% of 
cases 
24
. Motor weakness including hemiparesis is the most common focal finding 
and may be present in 40% of patients 
3,58
.  Seizures are more frequent in CVT 
than in other stroke types 
40
.  About 30 to 40% of patients with CVT can present 
with seizures either focal or generalized or with status epilepticus, especially with 
thrombosis of sagittal sinuses and cortical veins 
58,59
.  Isolated thrombosis of 
superficial cortical veins have marked tendency to produce partial seizures. About 
13% of patients complain of visual loss 
40
. Isolated cranial nerve palsy have been 
described with transverse sinus thrombosis
60
. Aphasia is seen in 19% of patients, 
for example, fluent aphasia occurs with left lateral sinus occlusion 
40
.  
22 
 
The progression of symtoms and signs in CVT is highly variable ranging from less 
than 48 hours to more than 30 days 
25
. 
Dural sinus thrombosis: 
Cavernous sinus thrombosis is a restricted form of CVT usually associated with 
sepsis spreading from the veins in the face, nose, orbits or sinuses. In general the 
presentation is with unilateral orbital pain, periorbital edema, proptosis, reduced 
visual acuity , papilloedema or 3,4,6,5 th nerve paresis. Anterior Cavernous sinus 
thrombosis causes marked chemosis and proptosis with cranial nerve 
involvement of 3,4,6, and ophthalmic division of fifth nerve. Posterior cavernous 
sinus thrombosis spreading to inferior petrosal sinus causes palsies of 6, 9, 10 
cranial nerves without proptosis and those involving superior petrosal sinus are 
accompanied by 5 th cranial nerve palsy. Patients are generally toxic and ill. 
Thrombus can propagate to the other side and cause bilateral signs. The 
differential diagnosis includes severe facial and orbital infection, and carotico-
cavernous fistula. 
In occlusion of sagittal sinus motor deficit (46%), focal (35%) and generalized 
(47%) seizures are frequent and isolated intracranial hypertension syndrome 
(17%) is infrequent 
40
. The exactly opposite scenario is observed with isolated 
23 
 
thrombosis of the lateral sinus. Multiple cranial nerve palsy (collet-sicard 
syndrome) is a rare manifestation of lateral sinus, jugular or posterior fossa vein 
thrombosis 
60
.  
Superficial cortical vein thrombosis: 
Isolated thrombosis of cortical veins produce large superficial (cortex and 
subjacent white matter) hemorrhagic infarctions and have marked tendency to 
produce partial seizures. Hemiparesis, incomplete hemianopia and aphasia are 
also characteristic of superficial thrombosis of cortical veins.Thrombosis of vein of 
Labbe causes infarction of underlying superior temporal lobe and occlusion of 
vein of Trolard implicates parietal cortex. The intracranial pressure is not elevated 
as it is in dural venous sinus occlusion. It should be suspected when there are 
multiple hemorrhagic infarctions in one hemisphere without a source of 
embolism or atherothrombosis. Isolated cortical vein thrombosis is probably 
underidentified and its diagnosis is difficult to confirm.  
Deep cortical vein thrombosis: 
Occlusion of vein of Galen and internal cerebral veins is least common and most 
obscure of venous syndromes. When the deep venous system is involved clinical 
24 
 
features are often severe with coma (67%), mental deficits (87%) and paresis 
(56%) that can be bilateral 
61
. 
Major clinical syndromes according to location of cerebral venous thrombosis.
 
CLINICAL COURSE: 
Classically the clinical course of CVT is unpredictable 
41
. In the ISCVT cohort the 
clinical course after admission was prospectively investigated, with the following 
conclusions: about one-fourth of patients deteriorate in status after admission. 
Neurological worsening may occur several days after admission and may consist 
of depressed consciousness, mental state disturbance, new seizures, worsening of 
previous symptoms or new focal deficit, increase in headache severity or visual 
25 
 
loss. About one-third of patients whose status deteriorates show new 
parenchymal lesions on repeat neuroimaging 
62
 .Patients with depressed 
consciousness on admission are more likely to deteriorate and those with seizures 
at onset are more likely to have repeated seizures. Deterioration is less frequent 
in patients presenting with isolated headache or with isolated intracranial 
hypertension syndrome. 
DIAGNOSIS:  
Often the diagnosis is not quickly considered but is stumbled on, particularly on 
brain MRI, after others have been considered and then excluded. 
CVT should be suspected when a patient develops signs of raised intracranial 
pressure with or without focal neurological deficits, papilloedema and seizures, 
particularly in the absence of vascular risk factors and when the CT-brain is 
normal .CVT may be the underlying cause in patients with features suggestive of 
diffuse encephalopathy, stroke, and rarely subarachnoid haemorrhage 
57
, 
psychosis, or migraine
63
. CVT should  be consisdered in all cases with Hemorrhagic 
infarcts especially if multiple or in nonarterial vascular territories 
64
. 
DIFFERENTIAL DIAGNOSIS: The differential diagnosis is wide and it includes 
arterial stroke, encephalitis, cerebral abscess, subdural empyema, and cerebral 
26 
 
vasculitis, as well as metabolic and toxic encephalopathies. Features 
differentiating CVT from arterial stroke are progression and fluctuation, more 
headache than usual for an arterial stroke, rather typically seizures, any infarct on 
brain imaging is seldom in a typically ‘arterial’ pattern and the patients are ‘too 
young’ for an ordinary stroke. 
INVESTIGATIONS: 
IMAGING: 
The American Heart Association (AHA) / American Stroke Association (ASA) 2011 
scientific statement on diagnosis and management of CVT recommends imaging 
of the cerebral venous system in patients with suspected CVT
 65
. 
CT Brain: 
CT-brain is a useful first line investigation particularly in sick patients in whom MRI 
is difficult to undertake. Signs detected in CT brain are divided into direct and 
indirect. Indirect signs are more frequent and include hemorrhagic or non 
hemorrhagic infarcts outwith the usual arterial territory, edema and intense 
contrast enhancement of falx and tentorium. Sometimes sub-arachnoid 
hemorrhage is seen, which is most unusual in either arterial infarcts or primary 
27 
 
intracerebral haemorrhage 
66
. Specific but less common changes include the 
direct signs, which correspond to visualization of thrombus itself, like empty delta 
sign indicating superior sagittal thrombosis, the cord sign and the dense triangle 
sign 
67
. All though CT brain is the most frequently performed imaging modality it 
can be normal in upto 25 to 30 % of cases 
40,24 
and direct signs are seen in only in 
one-third of patients 
65
. Thus CT brain has poor sensitivity compared to MRI brain.  
After intravenous contrast there may be gyral, falcine or tentorial enhancement 
and occasionally, the ‘empty delta’ sign (hypodensity in the middle of the 
posterior part of the superior sagittal sinus representing an area of no filling due 
to thrombus).    
The imaging changes in deep CVT are particularly striking with bilateral deep 
hemorrhagic infarction 
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  Figure1: CT brain showing CORD SIGN at the site of thrombosis of left superficial frontal vein. 
 
Figure 2: Contrast CT brain image showing  EMPTY DELTA SIGN (Superior Sagittal Sinus 
Thrombosis). 
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Figure 3: Plain CT Brain showing DENSE TRIANGLE SIGN (SUPERIOR SAGGITAL SINUS 
THROMBOSIS) 
 
MRI with MRV: 
The American Heart Association (AHA) / American Stroke Association (ASA) 2011 
scientific statement recommends MR with T2-weighted imaging and MR 
venography as the imaging test of choice for evaluation of suspected cerebral 
venous thrombosis 
65
. MRI brain with MRV is the most sensitive study for 
detection of CVT in the acute, subacute and in chronic phases of CVT 
1
. In the 
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acute phase (3 to 5 days), on T1-weighted images the thrombus appears 
isointense to brain tissue and in T2 –weighted images it appears hypointense. In 
the subacute phase, thrombus appears hyperintense in both T1 and T2 weighted 
images. After 2 to 3 weeks findings depend on whether or not the sinus remains 
occluded or whether it is partly or completely recanalised.  
However, MR venography has limited utility in patients with renal impairment. 
CT venography: 
CT venography is comparable to MR venography for the diagnosis of CVT
68,69
. It 
provides a rapid and reliable method for detection of CVT especially in patients 
with contraindications for MRI. 
Cerebral arterial angiography: 
Cerebral arterial angiography with venous phase imaging is consideres the gold 
standard investigation for the diagnosis of CVT
24
. But it is invasive and therefore 
performed when MRV/CT venography is inconclusive 
24
. There should be total or 
partial occlusion of at least one dural sinus on two projections. Often there is also 
occlusion of cerebral veins, late venous emptying and evidence of venous 
collateral circulation. A lack of filling of a transverse sinus is not due to congenital 
31 
 
hypoplasia if there is an appropriate sinus groove and jugular foramen on the 
plain skull X-ray. In obscure subacute encephalopathies, cerebral angiography or 
MR should always be done to rule out intracranial venous thrombosis before 
resorting to brain biopsy. 
LABORATORY: 
Thrombophilia testing: 
Because of high frequency of thrombophilia among patients with CVT, screening 
for hypercoagulable conditions should be performed in patients when needed. 
D-dimer: 
Although an elevated D-dimer supports the diagnosis of CVT, normal D-dimer 
level is not sufficient to exclude the diagnosis in patients with compatible clinical 
presentation 
70,71
. 
EEG: It is abnormal in about 75% of patients but the changes are nonspecific 
24
. 
CSF analysis: 
CSF is often abnormal in CVT including raised CSF pressure, elevated protein and 
pleocytosis 
24
. But it is not a routinely recommended investigtion. 
32 
 
Transcranial Doppler ultrasonagraphy and transcranial power or color Doppler 
imaging with or without the use of contrast agent were reported as potential non 
invasive techniques for diagnosis of CVT 
72
, but more studies are needed to 
determine the true clinical value of these methods. 
PROGNOSIS: 
Classically the clinical course of CVT is variable and difficult to predict for an 
individual patient .In general prognosis is less favourable in patients with both 
extremes of age. In the ISCVT cohort 79% of patients recovered completely 
40
. The 
current case fatality appears to be 10-20 % with further 10-20 % surviving with 
persistent deficit 
36
. Primary cause of death in acute phase of CVT is transtentorial 
herniation most frequently from large hemorrhagic lesion. 
In ISCVT, independent predictors of  poor outcome as defined by death or 
disability at 6 months were age > 37 years, male gender, deep CVT, presence of 
motor deficit, CNS infections, malignancy, hemorrhage on admission in  
CT/MRI,GCS score on admission < 9 
36,3
.  
Predictors of mortality at 30 days in the ISCVT cohort were depressed 
consciousness, mental status disorders, deep CVT, right hemispheric hemorrhage 
and posterior fossa lesion 
73
. 
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COMPLICATIONS: 
Complications with patients who survived acute phase of CVT are further venous 
thrombotic events, seizures and headache. Headache severe enough to require 
hospital admission occur in 14% of patients with CVT 
3
. In such case MRI with 
MRV are necessary to exclude recurrent CVT and other intracranial lesions and to 
document persistent venous occlusion, partial or complete sinus recanalisation or 
dural sinus stenosis. Seizures occur in upto 11% of patients 
40
. Severe visual loss 
due to intracranial hypertension can occur rarely
3
. 
Psychological and cognitive complaints are not uncommon among CVT survivors. 
About half of the survivors of CVT may become depressed or anxious and can 
manifest minor cognitive or language deficit which may preclude resumption of 
previous levels of professional activity 
74
.  
 Sequelae of CVT include cognitive and motor impairment, seizures, symptomatic 
persistent intracranial hypertension. 
Recurrence of CVT is rare and difficult to document. In the ISCVT cohort, 2.2% of 
patients had recurrent CVT and 4.3% had other thrombotic complications
40
 
especially DVT and pulmonary embolism.  
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In CVT, recanalisation of thrombosed vein and sinuses occurs in about 40 to 90 % 
of patients, especially with in the first 3 to 4 months 
75
. It is useful for patients 
with CVT to undergo MRI/MRV 3 to 6 months after CVT to document extent of 
recanalisation. However in adults recanalisation of occluded sinus is in no way 
related to outcome after CVT.  
TREATMENT: 
Treatment of CVT includes  
1. Antithrombotic treatment, 
2. Symptomatic treatment of intracranial hypertension, seizures, headache and   
visual failure. 
3. Etiological treatment of associated conditions and risk factors. 
Antithrombotic treatment: 
 The guidelines for the treatment of CVT was issued by the European federation of 
neurological societies (EFNS) in 2006 
76
. The EFNS guidelines advice that patients 
with CVT without contraindications to anticoagulation should be treated either 
with body weight adjusted subcutaneous low molecular weight heparin or dose 
adjusted intravenous heparin. On the basis of data from randomized controlled 
35 
 
trails and observational studies anticoagulation is recommended as safe and 
effective for treatment of CVT with or without intracranial hemorrhage on 
presentation 
65,76 
.Hence concomitant intracranial hemorrhage is not a 
contraindication for anticoagulation therapy.  
Aims of antithrombotic treatment are to recanalize the occluded sinus or veins, to 
prevent further propagation of thrombus, to prevent pulmonary embolism and to 
treat the underlying prothrombotic state inorder to prevent the recurrence and 
thrombus formation in other parts of body. 
 Risk of intracranial hemorrhage is <5% and systemic hemorrhage is <2% following 
heparin use and such hemorrhages do not influence the outcome
77
.  
There is no evidence regarding the safety and efficacy of antiplatelet drug therapy 
in CVT. 
Fibrinolysis:  
Evidences for the use of either systemic or local thrombolysis in the treatment of 
CVT are not sufficient
24
. Catheter related fibrinolysis may be considered at 
experienced centers for patients who have large and extensive CVT or who 
clinically worsen despite anticoagulation, possibly those without intracranial 
36 
 
hemorrhage. A review conducted on 169 patients with CVT showed substantial 
clinical benefit on treating those with severe disease manifestations with 
fibrinolysis 
78
. However, 17% of patients developed intracranial hemorrhage after 
fibrinolysis and clinical deterioration occurred in 5% of patients
78
. Mechanical 
endovascular disruption of thrombus can also be done.  
Surgical interventions: 
Surgical thrombectomy is reserved for the rare circumstance in which severe 
clinical deterioration occurs despite maximal medical therapy 
65
. 
Treatment of intracranial hypertension: 
 It includes elevating the head end of the bed, antiedema measures with osmotic 
diuretics, for example: mannitol, hyperventilation therapy to a target Paco2 of 30 
to 35 mmhg, decompression surgeries such as craniectomy or hematoma 
evacuation in patients with impending herniation 
79
.These measures are 
associated with improved clinical outcomes and can be life saving. If severe 
headache persist or if visual acuity is decreasing, repeated lumbar punctures, a 
lumboperitoneal shunt, stenting of a sinus stenosis or fenestration of the optic 
nerve sheath can also be done 
40
. 
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Treatment of the underlying cause: 
Any underlying cause should be treated, for example, lifelong anticoagulation 
should be given for patients with severe hereditary thrombophilia, patients with 
OCP associated CVT should never use OCPs again. But pregnancy or puerperium 
associated CVT is not a contraindication for future pregnancies because the risk of 
CVT in subsequent pregnancies among those with a history of pregnancy or 
puerperium associated CVT earlier is considered to be low 
3,45,80
. 
Long term management:  
AHA/ASA 2011 scientific statement recommends anticoagulation with oral 
vitamin K antagonist and a target INR of 2-3 for 3 to 6 months for those with 
provoked CVT and 6-12 months for those with unprovoked CVT and for those with 
mild hereditary thrombophilia 
65
. An indefinite period of anticoagulation is 
recommended for those with 2 or more episodes of CVT and for those with 1 
episode of CVT along with an associated severe thrombophilia 
65
. 
Seizures: 
The risk factors for subsequent early seizures in those with CVT are acute seizures 
and supratentorial lesions. Prophylactic antiepileptics should be considered in 
38 
 
patients with these risk factors 
59
. The long term risk of remote seizures is 
approximately 11% 
3
. The risk factors for remote seizures are acute seizures, 
motor deficit and supratentorial hemorrhagic lesions.  Long term antiepileptics 
are recommended for patients with these risk factors 
40
. Valproate is preferred to 
phenytoin and carbamazepine because of the lesser interactions with oral 
anticoagulants compared to the others and also because it can be used 
intravenously. If valproate is not tolerated, newer antiepileptics like Lamotrigine, 
Levetiracetam or Topiramate can be used.  
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MATERIALS AND METHODS 
Study design: Cross sectional study. 
Study material: 
The study was conducted on 45 radiologically confirmed cases of cerebral venous 
thrombosis admitted in Medicine and Neurology departments of Thanjavur 
medical college hospital during the period from November 2010 to November 
2012. 
Inclusion criteria: 
1. Patients with confirmed clinical and radiological diagnosis of cerebral venous 
thrombosis and 
2. With age >12 years were included in our study. 
Exclusion criteria: 
1. Patients whose clinical presentation could be explained by any other 
neurological disease.  
2. Patients without radiological evidence of CVT. 
 3.  Patients with age <12 yrs were excluded from our study. 
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Methodology: 
The study was conducted on 45 patients of cerebral venous thrombosis.  
The diagnosis of CVT was based on appropriate clinical findings supported by 
radiological evidence of CVT. Radiological diagnosis was based on established 
radiological criteria 
11-17
. 
We obtained Informed consent from all of our patients. 
In all the 45  patients detailed history including demographic factors,  type and 
duration of symptoms, onset of symptoms : acute (<48 h), subacute (48 h to <30 
days), and chronic (>30 days) 
18
, features suggestive of etiological factors, 
personal habits, comorbid illnesses, detailed menstrual and obstetric history in 
case of females was taken.  All the patients were subjected to detailed clinical 
examination including general, neurological and other systems examination. 
Assessment of consciousness level, Glascow coma scale
19 
score at the time of 
admission were also recorded in all patients. In GCS, the grading of severity is 
done as follows, severe (GCS score of ≤ 8), moderate (GCS score of 9-12), and mild 
(GCS score of 13-15) 
19
. 
Neuroimaging in the form of CT brain and MRI brain with MRA and MRV was done 
in all patients.  Details like presence of cerebral edema, haemorrhagic infarct, non 
41 
 
haemorrhagic infarct, presence of direct signs like cord sign, dense delta sign etc., 
occurrence of focal or diffuse subarachnoid haemorrhage in CT brain were 
recorded.  In MRI with MRV, type and number of sinuses involved, involvement of 
cortical veins, internal jugular vein extension, and laterality of the sinuses 
involved were noted. 
Investigations like complete blood count, erythrocyte sedimentation rate (ESR), 
blood urea,  blood sugar, serum creatinine, serum electrolytes, lipid profile, X-ray 
chest, Electrocardiogram, Elisa for Human Immunodeficiency Virus (HIV),VDRL, 
coagulation profile including bleeding time, clotting time, prothrombin time, 
activated partial thromboplastin time were done in all patients. Males with 
haemoglobin level of <13 g/dl and females with haemoglobin level of <12 g/dl 
were considered to have anemia in our study 
18
. 
Specific investigations like antinuclear antibody (ANA), antiphospholipid 
antibodies, tests for procoagulant states like protein C, protein S, antithrombin III 
(AT III) and serum homocysteine with an aim to detect the underlying etiology 
were done in certain patients as needed.  
Outcome at the end of the hospital stay was recorded in all patients. The 
modified Rankin score was used for outcome assessment 
20
. The modified Rankin 
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Scale (mRS) is commonly used for expressing the degree of disability of post 
stroke patients as well as those with other neurological disability. Hence it is 
widely used in the analysis of outcome in stroke clinical trials.  mRS was actually 
introduced by Dr. John Rankin of Stobhill Hospital Glasgow, Scotland 
21
  in 1957 
and was first modified by Prof. C. Warlow's group at Western General Hospital in 
Edinburgh 
22
. The currently used modified Rankin Scale was given by van 
Swieten, et al., in 1988
23
.  
The scoring is done from 0 to 6 as follows, 
0 - No symptoms. 
1 - No significant disability. Able to carry out all usual activities, despite some 
symptoms. 
2 - Slight disability. Able to look after own affairs without assistance, but unable to 
carry out all previous activities. 
3 - Moderate disability. Requires some help, but able to walk unassisted. 
4 - Moderately severe disability. Unable to attend to own bodily needs without 
assistance and unable to walk unassisted. 
43 
 
5 - Severe disability. Requires constant nursing care and attention, bedridden, 
incontinent. 
6 - Dead. 
In our study, good outcome was defined as modified Rankin Scale score of 0 to 2 
and poor outcome was defined as modified Rankin Scale score of >2 
5
. Factors 
associated with good and poor outcome were also analysed in our study. 
These demographic, clinical, laboratory, neuroimaging, outcome data were 
recorded and analysed using a standard proforma. Statistical analysis was done 
using SPSS software. Statistical analysis used descriptive, univariate and 
multivariate methods. Continuous variables were presented as mean, median 
and ± SD. Categorical variables were expressed as proportions and Fischer’s test 
was used to study the association in proportions. We estimated the relative risk 
and the resulting 95% Confidence Interval to study associations. P value of equal 
to or less than 0.05 was considered statistically significant. 
The study was approved by the ethical committee of our hospital.  
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OBSERVATION AND RESULTS 
Our study was conducted in 45 patients of cerebral venous thrombosis. We 
analysed the demographic characters, onset and type of symptoms, etiology and 
clinical features of the disease in these patients. All of them were subjected to 
imaging modalities like CT brain and MRI brain with MRA and MRV and we 
analysed the imaging characters of the disease in these 45 patients. We analysed 
the in hospital mortality rate and morbidity rate at the time of discharge.  We also 
analysed the factors associated with in hospital mortality, poor outcome defined 
as mRS score of >2 and good outcome defined as mRS score of ≤2 and we 
observed the following. 
Age distribution: 
Age range of our patients was 17 to 65 years. Of the 45 patients, 64% patients 
were in the age group of 21 to 30 years.  
 
 
 
 
 Table 1: Showing Age Distribution
Age range (in years) No. of patients
<21 
21-30 
31-40 
41-50 
>50 
 
Figure1: Showing Age Distribution
Mean age of our patients was 29.29 years and the median was 26 years.
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Distribution of sex in different age groups was also analysed and it showed that 
females formed the majority of the young patients in our study. 
Table 2: Showing sex distribution in different age groups 
Age (in years) 
Total no. of 
patients 
Males(No. of patients 
and percentage) 
Females(No. of 
patients and 
percentage) 
<21 4 1(25%) 3(75%) 
21-30 29 4(14%) 25(86%) 
31-40 7 3(42%) 4(58%) 
41-50 3 2(67%) 1(33%) 
>50 2 1(50%) 1(50%) 
 
 
 
 
 
 
 Figure 2: Showing sex distribution in different age groups
Peak age incidence was between 21 to 30 years with major contribution from 
females (86%). The mean age of females was lower (27.71yrs) than that of males 
(34.18 yrs). 
Sex distribution: 
Table 3: Showing sex distribution
Sex No. of patients
Male 
Female 
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 Percentage 
11 24.44 
34 75.56 
60% 80% 100%
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50%
Females
Males
 In our study, 75.56 % of patients were females.
Figure 3: Showing sex distribution
 Male female ratio was M:F=1:3.09.
Figure 4: Showing Male female ratio
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 Onset of symptoms: 
Onset of the symptoms was analysed as acute (
and chronic (≥30 days). Our observations were as follows,
Table4: Showing onset of symptoms
Onset No. of patients
Acute 
Subacute 
Chronic 
 
Figure 5: Showing onset of symptoms
About 53.33% of patients had subacute onset of symptoms. The median and  
mean duration of the presenting illness was  3 days and 6 days respectively.
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PRESENTING ILLNESS: 
The most common presenting symptom was headache (77.78%) followed by 
altered sensorium (40%), motor deficit (35.56%) and seizure (33.33%). 2(4.44%) 
patients presented with delirium. 
Table 5: Showing presenting symptoms 
Presenting symptoms No. of patients Percentage 
Headache 35 77.78 
Altered sensorium 18 40 
Motor deficit 16 35.56 
Seizure 15 33.33 
Delirium 2 4.44 
 
 
 
 
 
 
 Figure 6: Showing Presenting symptoms
Among the 15 patients who presented with seizure, 13 patients (86.67%) 
presented with generalized seizure. Focal seizure occured in just 2 (13.33%) 
patients and 2(13.33%) patients presented 
Figure 7: Showing seizure type 
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with status epilepticus. 
 
35
77.78%
40%
35.56%
33.33%
40 60 80 100
Percentage
No. of patients
50.00% 100.00%
86.67%
13.33%
Percentage
52 
 
Clinical features: 
 Papilledema was the most common clinical finding occurring in 24(53.33%) of 
patients. Focal motor deficit most commonly hemiplegia (11 patients) occurred in 
16 (35.56%) patients. 8(17.78%) patients had cranial nerve palsy. Most common 
nerve involved was the 6
th
 nerve. One patient who had a chronic onset presented 
with bilateral secondary optic atrophy (secondary to long standing papilledema).7 
(15.56%) patients were stuporous and 3(6.67%) patients were comatosed. 
Table 6: Showing clinical features 
Clinical feature No.of patients Percentage 
Papilledema  24 53.33 
Motor deficit 16 35.56 
Cranial nerve palsy 8 17.78 
Stupor 7 15.56 
Coma 3 6.67 
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Figure 8: Showing clinical features 
 
 None of our patients had sensory deficit, cerebellar signs or features of 
autonomic system involvement. 
Signs of meningeal irritation occurred in 2 of our patients. 
Majority of our patients had mixed features of the 3 classical syndromes namely 
Isolated Hypertension syndrome, focal syndrome and encephalopathy. However 
Isolated Hypertension Syndrome (IHS), consisting of headache with or without 
vomiting, papilledema, and visual troubles occurred in 13(28.88%) patients. All 
the 13 patients had headache; papilledema occurred in 9 of them and 4 had 
cranial nerve palsy, most common being the 6
th
cranial
 
 nerve palsy. 
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Etiology: 
Most common etiological factor noted in our study was puerperium. 
Among the 45 patients, about 24 females (53.33%) were in puerperium. They 
formed 70.59% of the total 34 females included in our study.The mean age of 
these females with puerperal CVT was lower (26.32yrs) than that of other females 
(32.4yrs). 
Among these 24 patients, 20(83.34%) patients had symptom onset within 2 weeks 
postpartum especially between 8 to 15 days postpartum. 
Table 7: Showing No. of days of onset of symptoms postpartum 
No. of days 
Postpartum No. of patients  Percentage 
1 to 7  7 29.17 
8 to 15  13 54.17 
16 to 30  2 8.33 
>30 2 8.33 
 
 
 Figure 9: Showing No. of days of onset of symptoms postpartum
Among the 24 patients, 10(41.67%) patients were of second gravida, 8(33.33%) 
were Primigravida and 6(25%) were of third gravida.
Among the 24 patients 6(25%) were post LSCS patients and none of these females 
had PIH in the antepartum period.
Dehydration, one of the important causes of CVT was noted in 3 of our patients 
who were post operative, post LSCS and alcoholic each.
One of our patient was a case of systemic lupus erythematosis. She was a 17 year 
old female who presented with acute onset headache and generalized seizure. 
She presented in status epilepticus. She had superior sagittal sinus thrombosis 
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and she tested positive for antiphospholipid antibody syndrome. She also had 
associated autoimmune thyroiditis. She had good recovery. 
Another patient tested positive for antiphospholipid antibody test and negative 
for dsDNA. She was a 22 year old female who presented with acute onset 
headache and papilledema with history of recurrent abortions. Her CT brain was 
normal but MRI with MRV showed superior sagittal sinus thrombosis and she 
recovered well.  
One patient had hyperhomocystenemia. He was a 21 year old male who 
presented with subacute onset of headache, vomiting, papilloedema and 
6
th
cranial nerve palsy. He had non haemorrhagic infarct in CT brain and 
thrombosis of left transverse sinus, straight and sigmoid sinus without 
involvement of SSS. 
 2 patients had CVT associated with meningitis. One patient was a 26 year old 
female, 3
rd
 gravida, who presented 20 days post LSCS with fever, headache, 
stupor and monoplegia. She had haemorrhagic infarct in CT brain and thrombosis 
of left side transverse sinus in MRI with MRV. The other was a 20 year old female 
who presented with subacute onset fever, headache, altered sensorium and SSS 
thrombosis. 
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Another patient, a known case of Polycythemia vera presented with Superior 
sagittal sinus thrombosis. He was a 29 year old male diagnosed earlier to have 
polycythemia vera and on irregular follow up, presented with subacute onset 
headache and delirium and haemorrhagic infarct in CT brain secondary to SSS 
thrombosis. 
One of our patients presented 4 days post partum with headache and generalized 
seizure, along with bleeding tendencies. She was a 30 year old female, who had 
developed intrauterine death of foetus at 30 weeks antepartum; foetus had been 
delivered by induction of labour 4 days prior to landing in our hospital. She was 
found to have disseminated intravascular coagulation. She had haemorrhagic 
infarct in CT brain and MRI with MRV showed superior sagittal sinus thrombosis. 
One of our patient was a known case of Bueger’s disease, on anticoagulant 
therapy. He was 37 year old male, chronic smoker, who had undergone 
amputation of right great toe 5 years back. He presented with 15 days history of 
headache, right hemiperesis and visual disturbances. He had bilateral secondary 
optic atrophy, and bilaterally weak popliteal, posterior tibial and dorsalis pedis 
pulses. His CT brain showed hypodensity in the left caudate nucleus, frontal and 
temporal region.MRI brain showed thrombosis of SSS, left transverse, sigmoid 
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sinus with subarachnoid haemorrhage in left fronto temporo parietal region and 
lacunar infarct in left lentiform and caudate nucleus.MRV showed thrombosis of 
all major dural venous sinuses except straight sinus with multiple venous 
collaterals and multiple lacunar infarcts in left basal ganglia,left deep 
periventricular white matter. 
Table 8: Showing Etiology 
Etiology 
No. of 
patients Percentage 
Pueperium 24 53.33 
Dehydration 3 6.67 
SLE 1 2.22 
APLA 2 4.44 
DIC 1 2.22 
Hyperhomocystenemia 1 2.22 
Meningitis 2 4.44 
Polycythemia vera 1 2.22 
Bueger’s disease 1 2.22 
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Figure 10: Showing Etiology 
 
RADIOIMAGING  
All the 45 patients included in our study were subjected to both CT brain and MRI 
brain with MRV. 
CT brain was done as an initial investigation and about 26.67% of our patients had 
normal study. Haemorrhagic infarct, characteristic of venous infarct occurred in 
55.56% of patients and non haemorrhagic infarct occurred in 17.78% of patients. 
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Table 9: Showing features in CT brain 
CT Brain 
No. of 
patients Percentage 
Normal study 12 26.67 
Nonhaemorrhagic infarct 8 17.78 
Haemorrhagic infarct 25 55.56 
 
Figure 11: Showing features in CT brain
 
Subarachnoid haemorrhage was noted in 2(4.44%) of our patients. Direct signs 
were observed in just 11.11% of our patients most commonly the dense delta sign 
suggesting superior sagittal sinus thrombosis. 
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MRI with MRV showed that among the individual sinuses, superior sagittal sinus 
(SSS) was the most common sinus involved (75.56% of patients), followed by the 
transverse sinus (46.67% of patients). Less commonly involved were the sigmoid 
and the straight sinus. 37.78% of patients showed involvement of more than 1 
sinus, most commonly involvement of both SSS and transverse sinus (26.67% of 
patients). 
Table 10: Showing involvement of sinuses by MRI with MRV 
Sinus involved 
No. of 
patients Percentage 
Superior sagittal sinus(SSS) 34 7.56 
Transverse 21 46.67 
SSS and Transverse 12 26.67 
Sigmoid 9 20.00 
Straight 3 6.67 
 
 
 
 
 Figure 12: Showing involvement of sinuses by MRI with MRV
Also 5 (11.11 %) patients showed involvement of more than 2 sinuses of which 
2(4.44%) had involvement of all 4 
Among the patients with transverse sinus involvement, right side transverse sinus 
was more commonly involved (11 patients) than the left (8 patients) and 2 
patients had bilateral transverse sinus involvement.
Among the 45 patients, 7 patients (15.56%) had extension of the thrombus into 
the internal jugular vein; 8 patients (17.78%) had associated involvement of 
cortical veins of which 2(4.44%) had extensive bilateral cortical veins thrombosis. 
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 None of our patients had isolated cortical vein thrombosis or deep vein 
thrombosis. 
OUTCOME: 
5 patients died during the in hospital stay. 8 patients had residual neurological 
deficit at the time of discharge. Hence the mortality rate in our study was 11.11% 
and morbidity rate was 17.78%. 
Table 11: Showing Mortality and Morbidity
Outcome No. of patients
Mortality 
Morbidity 
 
Figure 13: Showing Mortality and Morbidity
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 Percentage 
5 11.11 
8 17.78 
 
 
Morbidity
17.78%
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Among the 5 deaths, 1 (20%) was a male and 4 (80%) were females. One of these 
4 female deaths was a post partum death. 
Factors associated with in hospital mortality in our study were analysed. 
Coma at the time of admission was shown to be significantly associated with in 
hospital mortality. (p=0.0007; considered extremely significant). 
Table 12: Showing comparison of coma with survival and death 
Coma(No. of 
patients and 
Percentage) 
No coma(No. of 
patients and 
Percentage) 
Death 3(60) 2(40) 
Survival 0 40(100) 
By Fischer’s test p=0.0007 
 
 
 
 
 
 
 Figure 14: Showing Percentage of coma 
The association of age with in hospital mortality was assessed. The median and 
mean age of patients who died was greater (median=36yrs,mean=38.8yrs) than 
those who survived( median=26yrsmean=28.1yrs).
Also age ≥35 years was signific
Table 13: Showing comparison of age with death and survival
Age 
and percentage of 
patients)
Survival 
Death 
By Fischer’s test p=0.0471, considered significant.
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 Relative risk=4.000, 95% Confidence Interval: 1.431 to 11.183 (
approximation of Katz) 
Figure 15: Showing age distribution in death and survival
Association of GCS with in hospital mortality was studied.
Table 14: Showing comparison of GCS with death and survival
GCS <9
(No. and 
percentage of 
patients)
Death 
Survival 
By Fischer’s test P value is 0.0038, considered very significant. 
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GCS≥9 
(No. and percentage 
of patients) 
4(80) 1(20)
5(12.5) 35(87.5)
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 Relative risk = 6.400, 95% Confidence Interval: 2.525 to 16.220 (using the 
approximation of Katz.) 
Figure 16: Showing GCS score in death and survival
Poor outcome defined as modified Rankin Scale score of >2 was seen in 13 
patients.  Factors associated w
found that coma at the time of admission was significantly associated with poor 
outcome. 
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 Table 15: Showing comparison of coma with poor outcome
Poor outcome 
Good outcome 
By Fischer’s test, p=0.0116, considered significant.
Figure 17: Showing percentage of coma in good and poor outcome
Presence of motor deficit was also significantly 
shown below. 
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 Table 16: Showing comparison of motor deficit with poor outcome
Motor deficit 
(No.and Percentage 
of patients)
Poor outcome 
Good outcome 
By Fischer’s test, p=0.0001, considered extremely significant
 Relative risk = 5.152, 95% Confidence Interval: 2.433 to 10.905 (using the 
approximation of Katz).  
Figure 18: Showing percentage of motor deficit in  good and poor outcome
Presentation as Isolated intracranial hypertension syndrome was significantly 
associated with good outcome defined as mRS scale score of 
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 Table 17: Showing comparison of Isolated intracranial hypertension syndrome
poor outcome. 
Isolated intracranial 
hypertension syndrome
and Percentage of Patients)
Good 
outcome 
Poor 
outcome 
By Fischer’s test p=0.0195, considered significant.
 
Figure 19: Showing outcome in Isolated in Isolated intracranial hypertension syndrome.
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                                                             DISCUSSION 
The epidemiological factors, clinical presentation, etiological factors of CVT are 
highly variable. It is considered to be more common in South Asia and in the 
Middle East 
9,10
. It is a disease of children and young adults 
1,2,3
. 
In the largest clinical series, the International Study on Cerebral vein and dural 
sinus thrombosis (ISCVT) , the median age of patients with CVT was 37 years 
3
 and 
in a study conducted in Pakistan by  Khealani et al 
5 
,  median age was  35 years 
compared to  the median age in our study of 26 years. The mean age in our study 
was 29.29 years, lower than that reported by Khealani et al, Christo et al 
81
in a 
Brazilian study and Narayan et al 
18
in their study done in Hyderabad, India.  
Hence a lower mean and median age was observed in our study compared to 
most other studies 
5,18,81
. This could be because 64% of our patients were 
between the age range of 21-30 years of which 86% were females. 
Hence the mean age of females (27.71years) in our study was lower than that 
observed by Khealani et al
5
. We also observed that the mean age of females in 
our study was lower than that of males (34.18years) similar to the observations of 
Khealani et al
5
. 
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Though CVT can occur at any time from infancy to old age, most reported modern 
cases have been in adult women in association with puerperium
33
. It is more 
common in females than in males
3
.  
In our study, females formed the majority (75.56%) of the total 45 patients similar 
to that observed in most other studies 
5,81,82 
 except that of Narayan et al
18
  who  
observed a male predominance (53.7%). 
ISCVT reported a female male ratio of 2.9:1 
3
, a close approximate to our 
observation of 3.09:1. In contrary, Narayan et al observed a higher male female 
ratio of 1.17:1 
18
. 
The onset of symptoms was analysed as Acute (<48 hrs), Subacute (>48hrs to 30 
days) or Chronic (>30 days) in our study 
18
. According to literature, in ≥50% of the 
patients, the onset is subacute 
40
. In our study, 53.33% of patients manifested 
subacutely, followed by a lesser percentage of 42.22% manifesting acutely and 
just (4.44%) of patients manifesting chronically similar to the observations of 
Narayan et al
18
. 
The median duration of presenting illness was 3 days in our study, lower than the 
observation of 7 days by Khealani et al 
5 
but very much closer to the observation 
of 4 days by ISCVT
3
. 
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The mean duration of symptoms in our study it was 6 days as opposed to16.1 
days observed by Narayan et al
18
. 
As for as the presenting symptoms are concerned, upto 90% of patients with CVT 
complain of headache which is the most frequent symptom and often the initial 
one
40
.  By ISCVT, head ache was the only symptom in 9% of patients with CVT
40
. 
 In our study headache was the most common symptom (77.78%) similar to the 
observations of most other studies 
5,18,82,83
.  
Headache was observed as a sole symptom in 28.88% of our patients closer to 
that observed by Cristo et al 
81
 of about 33.3% whereas by ISCVT only 9% of 
patients manifested with sole headache 
40
. 
Other common symptoms noted in our study were altered sensorium (40%), focal 
neurological deficit and seizures similar to other studies 
5,82,83
. 
Next to headache, most common symptom observed in our study was altered 
sensorium, observed in about 40% of patients closer to 37% observed by Khealani 
et al
5
.  
Seizures are more frequent in CVT than in other stroke types 
40
. About 30 to 40% 
of patients present with seizures, either focal or generalized or with status 
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epilepticus
58,59
. Seizures was observed in 33.33% of our patients however seizure 
incidence was slighlty higher in other studies 
5,82,18
 . Similar to other studies 
5,81,82
, 
generalized seizure was more commonly observed than focal seizure in our study 
and status epilepticus was observed in just 4.44% patients. 
Focal neurological deficit, most commonly hemiplegia was observed in 35.56% of 
our patients closer to the observations of khealani et al
5
 and Ashjazadeh et al
82
. 
Comparison of the common clinical presentations in our study with other studies 
is shown in the table below. 
Symptoms  In our 
study 
Khealani et al
5 
Ashjazadeh et al
82 
Dutch-
European 
study
83 
Headache  77.78% 81% 93.54% 95% 
Altered sensorium  40% 37% 25% 39% 
Motor deficit 35.56% 45% 35.48% 43% 
Seizures 33.33% 39% 36.4% 47% 
 
Papilloedema occurs in about 50% of patients with CVT
24 
.Most common clinical 
finding observed in our study was papilledema similar to other studies
82,83
. Other 
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common findings were hemiplegia and cranialnerve palsy. Most common nerve 
involved was the 6 th cranial nerve. 
Coma was observed in 6.67% of our patients much lower than that reported in 
other studies
5,83
 . Most of our patients presented with a combination of the three 
classical syndromes of presentation in CVT namely, Isolated intracranial 
hypertension syndrome, Focal syndrome, and Encephalopathy. However Isolated 
intracranial hypertension syndrome was observed in 28.88% of our patients 
compared to 18.2 % by Narayan et al 
18
. Just 2 (4.44%) of our patients presented 
delirium. 
Pregnancy and puerperium are considered an important risk factor related to CVT 
in women 
3,32,45 
.  Studies from the west report <15% of their patients to be in the 
postpartum state 
3,84
. Douglas et al 
84,85   
reported that frequency of peripartum 
CVT is 8.9 t0 11.6 cases per 100000 deliveries. ISCVT reported obstetric CVT in 
only 20% of cases compared to studies from Mexico and India which report a 
much higher frequency 
3,6,32
. 
In our study 53.33% of patients were in postpartum state. Similar higher incidence 
of puerperal CVT was reported by the Pakistanian study 
5
.  
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Though peripartum CVT is especially common in less developed world countries 
with high pregnancy rates 
46
 there is a difference among different developing 
countries
5
. For example, Daif et al 
29 
from Saudi Arabia reported only 1 out of 40 
patients being in postpartum state and a very lower incidence of peripartum CVT 
was also reported in the Iranian study by Ashjazadeh et al 
82
 and the study done in 
Hyderabad, India by Narayan et al 
18
.However in our study puerperium was the 
leading cause of CVT. 
Douglas et al 
84
 reported by multivariate analysis that caesarean section and 
hypertension was significantly associated with peripartum and post partum CVT. 
The authors of the study suggest that the small increased risk with pregnancy 
induced hypertension might be due to a higher rate of caesarian section in 
women with hypertension and that there may be a cumulative effect of resistance 
to activated protein C during pregnancy together with decreased protein C levels 
following surgery 
86,87
 . However such an association of caesarean section or 
pregnancy induced hypertension was not seen in our study.  
 By literature, most common risk factor among women is use of oral contraceptive 
pills 
40
. Various studies have demonstrated the increased risk of CVT in patients 
using oral contraceptives and thrombophilia, particularly in the presence of 
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prothrombin gene mutation, factor V Leiden mutation and 
hyperhomocystenemia. Use of oral contraceptive pill has been an important risk 
factor for CVT in the west, with a reported incidence of 40 to 45% 
81
. The Iranian 
study by Ashjazadeh et al 
82 
 also reported a higher incidence of OCP induced CVT 
among their patients, who used them for a prolonged duration to avoid 
menstruation  during religious ceremonies like Ramadan fasting or Hajj . 
Whereas in our study use of OCP was not reported even in a single case. Similar 
lower incidence was reported by other Pakistanian and Indian studies 
5,18
. The 
reason could be due to lack of awareness of contraceptive methods among 
people visiting our hospital, who are mostly from rural areas in and around 
Thanjavur. 
Infective causes of CVT are rare nowadays, being responsible for only 6 to 12 % of 
patients with CVT
3,42
. However in developing countries, systemic and nervous 
system infections may remain an important cause of CVT (18%) 
5
. 
In our study, CVT secondary to meningitis was reported in 4.44% of cases in 
concordance with most of the recent studies 
3,82 
.Whereas in a Pakistanian study 
systemic and CNS infection was a leading risk factor, being observed in 18% of 
patients 
5
. 
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A prothrombotic condition was identified in 34% of patients in ISCVT cohort, 
being genetically determined in 22% patients 
3
. Most common prothromotic 
conditions are prothrombin gene mutation, factor V leiden mutation and 
anticardiolipin /antiphospholipid antibody syndrome.Less common are protein C, 
protein S deficiency and antithrombin III deficiency. Christo et al 
81 
and 
wysokinska et al 
88
 reported the incidence of thrombophilia as 10 to 13%. 
However the studies from Iran and Pakistan reported an incidence of just 4 to 5 
%
5,82
. 
Narayan et al reported 7.2% to be Anticardiolipin antibody positive and 12.3% as 
Protein C/S positive. In our study anticardiolipin antibody positivity was noted in 
4.44% of patients. 
Hyperhomocystenemia is a known risk factor for venous thrombosis. It results 
from low socioeconomic conditions secondary to deficient nutritional status, low 
plasma folate and vitamin B12 levels, which are associated with an increased 
risk of CVT in some developing countries 
89,90
.Hyperhomocystenemia was 
reported in 18.2% of cases by Narayan et al.
18
 as opposed to 4.5% by ISCVT 
3
 and 
9% by khealani et al 
5
. In our study just 2.22 % of patients had 
hyperhomocystenemia. 
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Anemia and alcoholism were reported as major risk factors by Narayan et al 
18
.In 
our study anemia was seen in 20% of patients and 13.33% of patients were 
alcoholics but the causative nature of these risk factors were not proven in our 
study. 
Imaging with CT is the most frequently done initial investigation in the diagnosis 
of CVT. Indirect signs are more common than direct signs which comprise direct 
visualization of thrombus. 
In our study, indirect signs were more frequently observed. Haemorrhagic infarct 
was the most common finding being noted in 55.56% of patients similar to the 
observations of most of the studies
5,18
. Direct signs were observed in just 11.11% 
of our patients most commonly the dense delta sign suggesting superior sagittal 
sinus thrombosis. 
The Superior sagittal sinus and the lateral sinuses are the most commonly 
affected sinuses in CVT, followed by the straight sinus and the cavernous sinus 
36,37
. 
Most common sinus involved in our study was superior sagittal sinus (75.56%) in 
concordance with most of the studies in literature 
18,24,33,82
. By contrast certain 
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studies 
81,88
reported a higher incidence of transverse sinus involvement than SSS 
involvement. 
Involvement of single sinus was seen in 62.22% of patients closer to 50% reported 
by khealani et al 
5
. 
Involvement of ≥2 sinuses was seen in 37.78% of patients in our study as against 
50% and 66% involvement by christo et al 
81
and wysokinska et al 
88 
respectively. 
By ISCVT 
4
 mortality occurred in 8.3% of their patients and most studies report a 
mortality rate of 10 to 20% 
7,36,82
. In our study mortality rate was 11.11%. 
Higher mortality than ISCVT could be due to tertiary care nature of our study 
centre. 
According to Bousser2000 
7
 and Girot et al 2007 
36
, 10-20% of patients survive 
with persistent deficits after CVT. In our study morbidity rate was 17.78%, lower 
than that reported in most other studies 
3,5,81
 the reason for which is unclear.Total 
recovery was seen in 71.11% of our patients compared to 79% by ISCVT 
3
and 
71.2% by Narayan et al 
18
. 
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On assessing the predictors of good outcome (defined as mRS scale score of ≤2 )  
we observed that patients who presented with isolated intracranial hypertension 
syndrome had good outcome ( p=0.0195) similar to the data in literature 
24
. 
In ISCVT, independent predictors of  poor outcome as defined by death or 
disability at 6 months were age > 37 years, male gender, deep CVT, presence of 
motor deficit, CNS infections, malignancy, hemorrhage on admission in  CT/MRI, 
GCS score on admission < 9 
36,3
. 
 Predictors of mortality at 30 days in the ISCVT cohort were depressed 
consciousness, mental status disorders, deep CVT, right hemispheric hemorrhage 
and posterior fossa lesion 
73
. 
Predictors of in hospital mortality in our study were age ≥35 years (p=0.0471), 
coma at the time of admission (p=0.0007) and GCS <9 ( p= 0.0038) and predictors 
of poor outcome ( defined as mRS scale score of >2)  in our study were coma at 
the time of admission (p=0.0116) and motor deficit (p=0.0001) similar to 
observations made by Ashjazadeh et al 
82
,  khealani et al 
5
 and ISCVT 
3
 except that 
the presence of haemorrhagic infarct  in initial CT brain was not associated with 
poor outcome in our study as opposed to above mentioned studies 
3,5,82
.  
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                                                          SUMMARY 
The summary of the observations made in our study are as follows, 
According to our study, 
1. CVT is more common in young females between the age group of 20 to 30 
years. 
2. CVT is 3 times more common in females than males. 
3. Majority of patients present subacutely between 3 to 30 days, with a mean 
duration of 6 days. 
4. Headache is the most common symptom and papilledema is the most 
common sign. 
5. Headache may be the isolated symptom in 28% of patients. 
6. Other common symptoms are altered sensorium, focal motor deficit, 
generalized seizures and delirium. 
7. Presentation with isolated intracranial hypertension is more common than 
isolated focal syndrome and isolated encephalopathy. 
8. Puerperium is the leading cause of CVT in our study with majority 
presenting within the first 2 weeks postpartum. 
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9. Oral contraceptive usage is a rare cause of CVT in our setting. 
 
10. Most common finding in CT Brain is haemorrhagic infarct. 
 
11. CT Brain can be normal in about 26 to 27 % of patients. 
 
12. Subarachnoid haemorrhage can occur in as few as <5% of cases. 
 
13. Superior sagittal sinus and right transverse sinus are the most common 
sinuses involved in CVT. 
 
14. Isolated cortical vein thrombosis and deep vein thrombosis are rare. 
 
15. Isolated intracranial hypertension syndrome is associated with good 
outcome. 
 
16. The mortality rate of CVT is about 11% and the morbidity rate is about 17%.  
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17. Hence in general, the prognosis is good in CVT, if promptly diagnosed and 
treated, except when the patient is ≥35 years of age or presents with GCS 
score of <9 or is comatosed at presentation.  
LIMITATION OF THE STUDY: 
An important limitation of our study is small sample size. We could have got more 
impressive results if the sample size had been large. 
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CONCLUSION 
Cerebral venous thrombosis, due to its wide spectrum of clinical presentation 
might be confused with other pathologies and hence the diagnosis may get easily 
missed or delayed.  The clinical picture can vary from headache refractory to 
analgesics to coma. Since headache is the most common symptom, CVT should be 
suspected whenever a young adult presents with symptoms and signs of raised 
intracranial tension with or without other neurological symptoms. Since 
presentation with headache as a sole symptom is not uncommon, CVT should be 
a differential diagnosis of significant headache in young adults even in the 
absence of other signs and symptoms and examination of the fundus to rule out 
papilledema might serve as an important tool in arriving at a diagnosis when 
suspected. 
CVT might be the underlying cause when a patient presents with diffuse 
encephalopathy, focal deficit, seizures, psychiatric symptoms or migraine.  Hence 
CVT should be suspected when a young adult presents with stroke especially in 
the absence of vascular risk factors. 
There is a definite variation in the risk factor profile of CVT from that of the west. 
Oral contraceptive use is not a major risk factor in our setting, whereas 
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peripartum CVT is the leading risk factor in our setting thus enforcing the 
importance of suspecting CVT in every peripartum female with neurological 
symptoms and also educating these females about the symptoms of the disease 
and the importance of reporting early to hospitals once symptoms appear. 
 CVT should always be suspected whenever imaging of the brain shows 
haemorrhagic infarct especially in non arterial territories. Since one may get 
misguided by a normal CT brain study, it is better to do more sensitive 
investigations like MRI and MRV whenever possible to confirm the diagnosis of 
CVT. 
Though the outcome of CVT is in general good if promptly diagnosed and treated, 
the predictors of poor outcome and death may help us to provide extra vigilance 
in case of at risk patients. 
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 KEY TO PROFORMA 
  
CT- Computed Tomography               
MRI- Magnetic Resonance Imaging 
MRA- Magnetic Resonance Angiography  
MRV- Magnetic Resonance Venography   
mRS - modified RANKIN SCALE 
                                                             
 KEY TO MASTER CHART 
 
M- Male 
 
F- Female 
 
N- No 
 
Y- Yes 
 
R- Right 
 
L- Left 
 
B/L- Bilateral 
 
CTD- Connective Tissue Disorder 
 
APLA- Antiphospholipid Antibodies 
 
CT- Computed Tomography 
 
IJV- Internal Jugular Vein 
 
LSCS- Lower Segment Caesarean Section 
 
 
 
PROFORMA  
CLINICAL PROFILE OF CEREBRAL VENOUS THROMBOSIS 
 
NAME :     AGE :   SEX: 
OCCUPATION :    INCOME:        In patient No.: 
DATE OF ADMISSION :  DATE OF DISCHARGE :   
 
HISTORY: 
 NEUROLOGICAL  SYMPTOMS:  
        Yes /No Duration 
Head Ache  
Type:  
Loss of Consciousness: 
Altered Sensorium : 
Convulsions : 
Number of  Episodes : 
  Duration: 
Focal: 
Generalised: 
Status Epilepticus: 
Post - Ictal state: 
Limb weakness      :              Upper limb        Lower limb 
      Right             
                                                              Left 
Speech Disturbance: 
Neuropsychiatric manifestations: 
Visual symptoms: 
h/s/o cranial nerve involvement: 
h/o sensory disturbances: 
 
h/o bladder/ bowel disturbances: 
h/o ataxia: 
h/s/o autonomic dysfunction: 
 
ONSET OF SYMPTOMS:                                   Yes/No 
 
ACUTE (<2 days):         
SUBACUTE (3 days to 30 days):       
CHRONIC (>30 days):        
 
NON- NEUROLOGICAL SYMPTOMS:   
Yes /No   
 Fever 
 Nasal discharge 
 Ear Ache / Ear Discharge 
 Diarrhea/ vomiting 
 
SYMPTOMS SUGGESTIVE OF EIOLOGY: 
RHEMATOLOGICAL SYMPTOMS 
 
Yes /No    
 Arthralgia 
 Oral ulcer 
 Skin rash 
 Alopecia 
 Photosensitivity 
 Raynaud’s Phenomenon 
 Others  ( Specify ) 
 
 
 
 HISTORY SUGGESTIVE OF THROMBOPHILIA        Yes/No 
 
H/O  prior  Deep Vein Thrombosis/ Pulmonary embolism 
H/O  prior  Cerebral Venous Thrombosis:                         
H/O  recurrent abortion (in females):                             
           
DRUG HISTORY                                                        Yes/No 
 Oral Contraceptive Pill: 
 Anticoagulants: 
 Others: 
MENSTURAL HISTORY  :                               
 
 
 
OBSTETRIC HISTORY              
 
 GRAVIDA : 
 PARA:  
 History of Pregnancy induced hypertension / Eclampsia :                                         
 Normal vaginal delivery :                                               
  Lower Segment Caesarean Section:                                                                             
 Time of onset of symptoms since delivery : 
 
PAST HISTORY  :                                         Yes/No 
 Diabetes mellitus : 
 Systemic hypertension : 
 Coronary artery disease: 
 Valvular Heart Disease: 
 Tuberculosis: 
 Seizure Disorder : 
 Migraine              :       
 Thyroid Disorder (hyper / hypo ): 
 Others (Specify ): 
 h/o recent surgery: 
 
FAMILY HISTORY                                    Yes/No 
 
 Diabetes mellitus :    
 Systemic hypertension: 
 Tuberculosis: 
 Connective tissue disorder:    
 h/o Deep Vein Thrombosis: 
 h/o Cerebral Venous Thrombosis: 
 
PERSONAL  HISTORY                               Yes/No 
 
 Smoking  
 Alcohol 
 Drug addictions / abuse 
 
EXAMINATION: 
 
GENERAL                                  Yes/No         
Febrile  
Pallor 
Icterus 
Cyanosis 
Clubbing 
Edema 
Lymphadenopathy 
Sign of dehydration  
Pulse rate: 
Blood Pressure: 
Signs suggestive of Connective Tissue Diseases (if any): 
 
CENTRAL NERVOUS SYSTEM EXAMINATION  
Higher functions   
 Consciousness : 
  Normal : 
  Drowsy : 
  Stupor : 
  Coma  : 
Glasgow Coma Scale :    
Orientation                       : 
Speech   : 
Memory                            : 
Other higher function Abnormality (if any): 
FUNDUS   : 
 CRANIAL 
NERVES Yes/No 
I  
II  
III          
 IV           
VI 
V 
VII  
VIII 
IX 
X 
XI 
XII 
 
 
SPINOMOTOR SYSTEM                   Right   Left    
Bulk  
Tone  - Upper Limb 
- Lower Limb 
Power - Upper Limb 
  - Lower Limb 
Reflexes 
Superficial Reflexes  : Corneal  
     Conjunctival 
     Abdomen 
     Plantar 
 
 
 
 
Deep tendon Reflexes 
       Right   Left 
  Upper Limb 
  Lower Limb 
Gait: 
Sensory system: 
 
          Yes/No   
Cerebellar involvement : 
 Involuntary movements:  
Autonomic involvement : 
Meningeal signs: 
 
OTHER SYSTEMS                                          Yes/No  
Cardiovascular system: 
Respiratory system: 
Abdomen: 
 
 DIAGNOSIS : 
 
 
 
 
 
 
 
 
 
 
 
INVESTIGATIONS 
 
Complete blood count:     
Random blood sugar:     
Renal function test:  
Electrolytes: 
Lipid profile: 
Chest X-ray: 
Electrocardiogram: 
Echocardiogram: 
Ultrasound abdomen: 
Doppler lower limb: 
Veneral Disease Research Laboratory: 
 ELISA for Human Immunodeficiency Virus: 
Bleeding Time: 
Clotting Time: 
Activated partial thromboplastin time: 
Prothrombin Time: 
International normalised ratio: 
OTHERS (as required)  : 
 
CT- BRAIN:                                               Yes/No 
Hemorrhagic infarct: 
Non hemorrhagic infarct: 
Cerebral edema: 
Enhancement of falx and tentorium: 
Sub-arachnoid hemorrhage: 
Cord sign: 
Dense triangle sign: 
Empty delta sign: 
MRI brain WITH MRA & MRV:    
                               
                                                                    Yes/No     
 Superior sagittal sinus: 
Transverse sinus: Right/Left 
Straight sinus: 
Sigmoid sinus: 
Deep cerebral veins thrombosis: 
Internal Jugular Vein extension: 
Cortical veins thrombosis: 
Unilateral / Bilateral disease: 
 
OUTCOME:                                          Yes/No                               
Death: 
Disability: 
mRS score: 
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